RE:RE:RE:RE:60 product pipeline...Remember, the company can delever by making very attractive product acquisition. It grows the ebitda so the debt/ebitda goes down. D/ebitda will be 5.5x or lower at year-end. Cinven (private equity) had Amco (Amdipharm Pharma) at 6.5x d/ebitda. So private equity could add leverage (check out the Amco 2014 annual review) and with the free cash flow, generate excellent returns. Even if they pay $55 to $65 U.S.
also look at Horizon Pharma and Depomed: specialty Pharma has bottomed are looking to break out. Valeant has their own issues (lawsuits, etc....). Their shares are lagging, but not a good proxy for CXR.